Agenus (AGEN) to Post Earnings on Thursday

Agenus (NASDAQ:AGEN) will likely be issuing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Agenus to post earnings of $0.05 per share and revenue of $34.00 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 7:30 AM ET.

Agenus (NASDAQ:AGEN) last released its quarterly earnings results on Monday, May 11th. The biotechnology company reported $1.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.10 by ($1.08). The firm had revenue of $33.74 million for the quarter, compared to analyst estimates of $129.50 million. Agenus had a negative return on equity of 31.66% and a net margin of 50.49%. On average, analysts expect Agenus to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Agenus Trading Up 1.0%

Shares of NASDAQ AGEN traded up $0.07 during midday trading on Tuesday, reaching $7.89. 417,432 shares of the stock were exchanged, compared to its average volume of 2,160,557. The company has a market capitalization of $353.32 million, a P/E ratio of 4.96 and a beta of 1.55. Agenus has a 52-week low of $2.71 and a 52-week high of $8.70. The stock has a 50 day moving average price of $4.14 and a 200-day moving average price of $3.71.

Institutional Investors Weigh In On Agenus

Several institutional investors have recently bought and sold shares of AGEN. EP Wealth Advisors LLC purchased a new position in shares of Agenus in the 4th quarter valued at $31,000. Quadrature Capital Ltd acquired a new stake in Agenus in the 4th quarter valued at $54,000. Squarepoint Ops LLC acquired a new stake in Agenus in the 3rd quarter valued at $54,000. Jump Financial LLC purchased a new position in Agenus in the second quarter valued at about $55,000. Finally, Acadian Asset Management LLC acquired a new position in shares of Agenus during the first quarter worth about $58,000. 61.46% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on AGEN. HC Wainwright raised their target price on shares of Agenus from $23.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Wall Street Zen upgraded Agenus from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings reissued a “sell (d)” rating on shares of Agenus in a research note on Tuesday, June 16th. Zacks Research cut Agenus from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Finally, B. Riley Financial reaffirmed a “buy” rating and issued a $14.00 price objective (up from $8.00) on shares of Agenus in a research report on Thursday. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $22.00.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.